In:
The Oncologist, Oxford University Press (OUP), Vol. 19, No. 8 ( 2014-08-01), p. e4-e4
Abstract:
Sarcopenia caused by hyperthyroidism from thyroid-stimulating hormone-suppressive therapy is one possible explanation for sorafenib dose-limiting toxicity in patients with differentiated thyroid cancer (DTC). Another possible explanation is that DTC patients in the considered trial were treated approximately twice as long as the renal-cell and hepatocellular carcinoma patients.
Type of Medium:
Online Resource
ISSN:
1083-7159
,
1549-490X
DOI:
10.1634/theoncologist.2014-0186
Language:
English
Publisher:
Oxford University Press (OUP)
Publication Date:
2014
detail.hit.zdb_id:
2023829-0